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Background: Platelets play a fundamental role in maintaining hemostasis and have been shown to participate in
hematogenous dissemination of tumor cells. Abundant platelets were detected in the tumor microenvironment
outside of the blood vessel, thus, platelet -tumor cell interaction outside of the bloodstream may play a role in
regulating primary tumor growth and metastasis initiation. However, it is unclear that platelet depletion affects
tumor vessel structure and dynamics.
Methods: Using thrombocytopenia induction in two different tumor-bearing mouse models, tumor tissues were
performed by Westernblotting and immunohistochemical staining. Vascular permeability was evaluated by
determination of intratumoral Evans blue and Miles vascular permeability assay. Furthermore, microdialysis was
used to examining the intratumoral extracellular angiogenic growth factors (VEGF, TGF-β) by ELISA.
Results: Platelet depletion showed no change in tumor growth and reduced lung metastasis. Platelet depletion led
to reduced tumor hypoxia and Met receptor activation and was associated with a decreased release of MMP-2, 9,
PAI-1, VEGF, and TGF-β. Tumor vessels in platelet-depleted mice showed impaired vessel density and maturation.
Conclusions: Our findings demonstrate that platelets within the primary tumor microenvironment play a critical
role in the induction of vascular permeability and initiation of tumor metastasis.
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In addition to hemostasis, circulating platelets play a vital
role in tumor progression and metastasis [1-3]. The
proposed molecular mechanisms mainly involve the
hematogenous dissemination of tumor cells. Platelet inter-
action with tumor cells is known to contribute to metasta-
sis by shielding tumor cells from NK cell destruction,
aiding endothelial attachment, releasing angiogenic and
growth factors such as vascular endothelial growth factor
(VEGF) and tumor growth factor-β (TGF-β), and assisting
tumor cell invasion. Experimental evidence suggests that
the depletion of platelets results in anti-tumor dissemin-
ation in thrombocytopenic mice [4-7]. The leaky tumor
vasculature allows platelets to come in contact with the* Correspondence: wuji@missouri.edu
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unless otherwise stated.tumor and deposit multiple angiogenic factors near tumor
cells, which in turn contribute to tumor progression. A re-
cent study demonstrated that abundant platelets were de-
tected in the primary tumor microenvironment away from
the vasculature [7], and thus, it is likely that the pro-
metastatic role of platelets is not limited to circulating
dissemination.
The tumor microenvironment is critical in facilitating
tumor growth and metastasis, and hypoxia of the micro-
environment is believed to directly affect the ability of
tumor cells to metastasize [8,9]. The role of platelets in
tumor angiogenesis and the modulation of vessel perme-
ability are well established, whereas their effect on the
tumor microenvironment is still undefined. It has been
proposed that platelets may play a direct role in the
mobilization of primary tumor cells to vessels for metas-
tasis. However, there has been no direct evidence for
how platelets cause increased local invasion. Previous
studies demonstrated that the depletion or reduction ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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metastasis of various tumors [3,7,10,11], and the require-
ment of functional platelets for circulating tumor dis-
semination has been confirmed in many experimental
settings. The current study was designed to test the hy-
pothesis that platelets influence metastasis by mediating
tumor vessel structure and dynamics.
Methods
Animals
All animal procedures described in this study were per-
formed using 6- to 8-wk-old C57BL/6 J mice or BALB/c
mice (purchased from The Jackson Laboratory). Animal
use was approved by the Animal Experimentation Com-
mittee of Luzhou Medical College.
Cell culture
Murine B16/F10 melanoma cells or 4 T1 mouse mam-
mary epithelial cancer cells were obtained from Ameri-
can Type Culture Collection (Manassas, VA, USA), and
grown in DMEM media supplemented with 10% fetal
calf serum (FCS), 100 U/ml penicillin and 100 U/ml
streptomycin.
Tumor cell implantation
Mice were anesthetized with ketamine/xylazine, and
1X106 B16/F10 melanoma cells or 4 T1 mouse breast
cancer cells (8 mice /each group) were implanted sub-
cutaneously in the back. Tumor volumes were measured
every 3 days using Vernier calipers, and volumes were
calculated using a standard formula (length x width2 x
0.52). Mice were sacrificed when tumor growth reached
25 days post-cancer cell implantation.
Induction of thrombocytopenia
When the average B16/F10 tumor size reached ~ 500 mm3,
or 4 T1 tumor size reached ~ 250 mm3, thrombocytopenia
was induced by intraperitoneal (i.p.) injections every 3 days
of 2.5 μg/g mouse platelet-depleting antibody (polyclonal
anti-mouse GPIbα rat IgG; emfret Analytics). Control mice
were injected with a nonimmune rat polyclonal IgG (emfret
Analytics). Thrombocytopenia was evaluated by blood
count. The i.p. injection of the depleting antibody resulted
in ≥95% reduction in circulating platelets at 12 h post-
injection in all mice.
Quantification of metastasis
The metastatic area of lung was quantified as described
previously [12]. Briefly, HE staining of paraffin-embedded
lung sections was performed, and light photomicrographs
were taken from the bilateral lobe of the lung and recon-
structed using the Adobe Photoshop CS4 function. Metas-
tases were identified via hispathological analysis, and the
metastatic area was quantified as a percentage of the totalreconstructed lung area using NIH ImageJ software. High-
magnification images of the metastatic area were obtained
by magnifying the original images by 40×.
Immunoblotting
Tumor tissues were homogenized in RIPA buffer (Sigma).
Equal amounts of protein were subjected to SDS-PAGE
and transferred to polyvinylidene difluoride membranes by
electroblotting. After blocking, the membranes were incu-
bated with phosphospecific and nonphosphospecific anti-
bodies directed against Met, HIF-1α, Angiopoietin 1,
Angiopoietin 2, VE-cadherin, PAI-1, MMP-9, and β-actin.
Relative band density for Western blotting was determined
using ImageJ gel analysis software.
Immunofluorescence and quantification
To quantify pericyte coverage (α-SMA, red channel), we
drew a region of interest (ROI) close to each blood ves-
sel (PECAM-1, green channel) and calculated the mean
fluorescence intensity of the red and green channels
using the Zeiss Confocal Software Histogram Quantifica-
tion Tool. Values were expressed as a percentage of red
to green. Quantification was performed by analyzing at
least 3 sections and 3 fields per tumor.
Quantification of VEGF and TGF-β levels
Microdialysates were analyzed for VEGF and TGF-β
protein content using commercial quantitative immuno-
assay kits (R&D Systems). The analyzed proteins were
normalized to the total protein content and expressed as
pg/mg protein.
Tumor hypoxia analysis
Tumor hypoxia was quantified as described previously [13].
Tumor tissues were collected 2 hours after injection of
60 mg/kg pimonidazole hydrochochloride (HP2100 Hypox-
yprobe Kit-Plus; Natural Pharmacia International Inc.) into
mice. The formation of pimonidazole adducts was detected
by immunostaining with Hypoxyprobe-1-Mab 1 antibody
according to the manufacturer’s instructions. Images were
captured and analyzed using an Olympus (DP70) micro-
scope and then evaluated using the the Adobe Photoshop
CS4 function. Quantification was performed by analyzing
at least 3 sections and 3 fields per tumor.
Determination of intratumoral Evans blue
Mice were injected i.v. with 100 μL 5% Evans blue.
Three hours after injection, the tumors were isolated
from the surrounding tissue, weighed, and placed in
0.5 ml formamide. Three days later, the supernatants
were measured by reading the absorbance at 620 nm.
Data were presented as micrograms of Evans blue dye
per gram of tissue.
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The miles assay was performed as previously described
[14]. Briefly, mice were administrated Evans blue dye.
VEGF (300 ng in 15 μl) or saline was injected subcuta-
neously into the dorsal surface of the right and left ears,
respectively. After 30 minutes, mice were euthanized
and their ears removed, oven-dried at 55°C, and
weighed. The Evans blue dye was then extracted from
the ears using 500 μl of formamide for 24 hours at 55°C,
and the absorbance of extracted dye was measured at
630 nm.
Tumor perfusion assay
Tumor perfusion assay was performed as previously de-
scribed in detail [15]. Briefly, Mice were injected with
0.2 ml of 25 mg/ml FITC-dextran (molecular weight
2,000,000; Sigma-Aldrich, St. Louis, MO, USA) by tail vein
20 min before being killed. Whole blood samples were col-
lected and stored at 4°C in the dark. Blood samples were
centrifuged at 15000 rpm for 10 min at 4°C and superna-
tants collected for fluorescence assay. Tumors were har-
vested, weighed, and treated with dispase (1:10 dilution,
1 ml per 0.5 g tumor tissue) at 37°C in a shaker for 4 h in
the dark. Tumor tissues were then homogenized and cen-
trifuged at 16000 rpm for 15 min. Supernatants were col-
lected and stored in the dark at 4°C. Supernatant
fluorescence was measured in a reader (Molecular Device,
USA). The ratio of tumor fluorescence/plasma fluorescence
reflects the extent of tumor blood vessel perfusion.
Determination of intratumoral hemoglobin content
Tumors were excised from the backs of the sacrificed ani-
mals, weighed, homogenized in Drabkin's reagent (Sigma),
and centrifuged (2000 × g; 10 min). The hemoglobin con-
tent in the supernatants was measured by reading the ab-
sorbance at 540 nm.
Microdialysis for protein sampling in vivo
Microdialysis was performed as previously described in de-
tail [16]. Briefly, mice were anesthetized, and microdialysis
probes (CMA/20, 0.5-mm diameter, PES membrane length
4 mm, 100-kDa cutoff, CMA/Microdialysis) were inserted
into tumor tissue sutured to the skin, connected to a
CMA/102 microdialysis pump (CMA/Microdialysis) and
perfused at 0.6 μL/min with saline (154 mmol/L NaCl) con-
taining 40 mg/mL dextran (Pharmalink). The outgoing
microdialysates were collected on ice and stored at −80°C
for subsequent ELISA analysis.
Statistical analysis
Data are presented as the mean ± SEM and were ana-
lyzed by ANOVA and by unpaired two-tailed Student's t
test. P values of <0.05 were regarded as statistically
significant.Results
Platelet depletion showed no change in tumor growth
and reduced lung metastasis
Previous studies demonstrated that circulating platelets
play a shielding role in cancer cell dissemination and
hemorrhagic metastasis [1-3]. To evaluate the role of
platelets in primary tumor progression and metastasis,
we performed thrombocytopenia induction in a tumor-
bearing mice model. B16/F10 melanoma cancer cells
were implanted into the backs of C57BL/6 J mice.
Primary tumor growth was monitored, and when tumors
reached ~500 mm3 in size, anti-GPIbα or rat IgG was
injected into platelet-depleted or control mice, respect-
ively, every 3 days until 24 days post-injection
(Figure 1A). Until the experimental endpoint, platelet-
depleted mice showed no change in tumor growth
(2777 ± 300 mm3 Vs. 2956 ± 180 mm3, p > 0.05)
(Figure 1A, B) compared to control mice, while B16/F10
tumor-bearing platelet-depleted mice exhibited a signifi-
cant reduction in lung metastasis compared to control
mice (Figure 1C).
To further investigate whether PLT depletion leads to re-
duced metastasis in other tumor types, we subcutaneously
implanted 4 T1 mouse mammary epithelial cancer cells
into BALB/c mice. The mice were then treated with anti-
GPIba or rat IgG, respectively, when tumors reached
250 mm3 in size. Similarly, platelet-depleted mice showed
no change in tumor growth compared to control mice
(Additional file 1: Figure S1A). PLT-depleted tumors dem-
onstrated large dark cores, associated with increased
hemorrhagic areas, while 4 T1 tumor-bearing platelet-
depleted mice exhibited a significant reduction in lung
metastasis compared to control mice (Additional file 1:
Figure S1B). These results further support that platelets
play a role in tumor metastasis in different types of tumors.
Platelet depletion reduces blood vessel density, vessel
maturation, and perfusion
Because proangiogenic growth factors released from plate-
let granules could affect tumor vessel formation, we exam-
ined vessel density and coverage in the tumors by using
anti-PECAM-1 and anti-α–SMA double staining. PECAM-
1-positive microvascular density was significantly lower in
platelet-depleted B16/F10 tumors compared to control tu-
mors (Figure 2A). Coverage of intratumoral microvessels
by α–SMA-positive mural cells was also significantly lower
in platelet-depleted B16/F10 tumors compared to control
tumors (Figure 2A, B). To better characterize the role of
platelets in tumor blood vessel function, we further studied
the perfusion of the tumor vasculature in platelet-depleted
and control mice. We evaluated the mice based on the ratio
of fluorescence intensities within the plasma and tumor
following injection with FITC-dextran (MW 20,000). We
found that platelet depletion significantly reduced blood
Figure 1 Platelet depletion showed no change in tumor growth but reduced lung metastasis. (A) Orthotopic implantation of B16/F10
tumor cells into C57B6/L mice followed by injections every 3 days of GPI or control antibody after the tumors reached ~500 mm3. (B) Total
tumor volumes at the experimental endpoint (24 days). (C) Representative images of H&E-stained lung sections. Scale bar, 5 μm. Arrows point to
metastatic areas. Number of metastatic lung nodules in the lungs of these mice. Error bars display mean ± SEM; asterisks denote significance
(*p < 0.05). (D) Western blot analysis of p-Met, total Met, and β-actin expression in tumors from control and PLT-depleted mice. Quantification of
western blot analysis for total Met (normalized to β-actin) and p-Met (normalized to β-actin), Error bars display mean ± SEM; asterisks denote
significance (*p < 0.05) (n = 6 for each group).
Figure 2 Platelet depletion reduces tumor blood vessel density, pericyte coverage and perfusion. (A) Representative images of
immunostaining of tumor sections for PECAM-1 (green) and α-SMA (red). Scale bar, 50 μm. Quantitative assessment of PECAM-1-positive blood
vessels (B) and α-SMA /PECAM-1-positive cells (C) in B16/F10 tumors from platelet (PLT)-depleted and control mice. The results were represented
as the mean percentage of area ± SME (n = 6). (D) Tumor blood vessel perfusion assay using FITC-dextran in vivo. Following 2 weeks of treatment
with GPI or control antibody, tumor-bearing mice were injected (iv) with 0.2 ml FITC-dextran (25 mg/ml) for 20 min. Tumors and whole blood
were collected, processed, and centrifuged. Fluorescence was measured in the supernatants from tumor tissue and whole body plasma. The ratio
of tumor to plasma fluorescence reflects the extent of tumor perfusion. The results are expressed as the mean ± SEM. *p < 0.05. (n = 6 for
each group).
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(Figure 2C).Platelet depletion induces vessel leakage
Vascular permeability has been correlated to vessel matur-
ation during tumor growth [17,18]. We therefore examined
whether the reduced coverage of pericytes to tumor micro-
vessels in platelet-depleted mice affected tumor vascular
permeability. Platelet-depleted tumors exhibited a 3.2-fold
increase in Evans blue extravasation compared to control
tumors (189 ± 25.3 Vs. 59.3 ± 7.9 ng/mg tumor dry weight,
p < 0.05) (Figure 3A). Furthermore, we used the Miles assay
to measure vascular leakage in the skin of control and PLT-
depleted mice. As shown in Figure 3B, VEGF-mediated
hyperpermeability was significantly increased in the PLT-
depleted mice compared with that in the WT mice. Taken
together, these results indicated that platelet depletion has
an effect in increasing vascular permeability in vivo.
We measured the intratumoral hemoglobin content,
which reflects the level of erythrocyte extravasation. The
hemoglobin content in the tumors of platelet-depleted
mice was significantly higher than in control mice
(172.11 ± 20.2 g/L/g Vs. 110.28 ± 12.4 g/L/g, p < 0.05)
(Figure 3C). Collectively, these data strongly suggest that
reduced coverage of pericytes in tumor vessels might beFigure 3 Platelet depletion increases vessel permeability. (A) Orthotop
followed by injections every 3 days of GPI or control antibody after the tum
Evans blue, i.v.; 30 min) at the experimental endpoint (24 days). Evans blue
*,p < 0.05. (B) Photographs of Evan’s blue dye leakage 30 minutes following
skin of control and platelet depletion mice. n = 3 for each group. (C) Comp
PLT-depleted mice, *p < 0.05. (n = 6 for each group). (D) Western blot analy
PLT-depleted mice. Quantification of Western blot analysis for VE-cadherinanother main origin of the increased vascular tumor
leakage observed in platelet-depleted mice.
To better investigate the molecular mechanisms by
which platelet depletion induced vessel leakage in the
tumor microenvironment, we evaluated the expression
of VE-cadherin protein, which is a critical EC-specific
adhesion molecule in regulating vascular permeability.
We found that the VE-cadherin protein level was re-
duced in platelet-depleted tumors compared to controls
(Figure 3D), suggesting that platelet depletion-induced
vascular leakage is associated with a reduction of VE-
cadherin expression.
Platelet depletion reduced hypoxia, HIF-1α expression,
and Met activation
To further gain insight into the molecular mechanisms
associated with reduced metastasis resulting from
platelet depletion, we first assessed hypoxia levels by
examining pimonidazole adduct formation in the tumors
of platelet-depleted and control mice and found de-
creased hypoxic levels in the platelet-depleted tumors
(Figure 4A). In addition, expression of the hypoxia-
inducible transcription factor HIF-1α was also signifi-
cantly reduced in the tumors of platelet-depleted mice
(Figure 4B), suggesting that platelets are involved in
tumor hypoxia.ic implantation of B16/F10 tumor cells into C57B6/L mice were
ors reached ~500 mm3. Evans blue was then injected (100 μL 5%
was then extracted and quantified spectrophotometrically at 620 nm.
intradermal injection of either saline or VEGF into the shaved dorsal
arison of intratumoral hemoglobin content among control and
sis of VE-cadherin expression in tumors from control and
(normalized to β-actin).
Figure 4 Platelet depletion reduced hypoxia, HIF-1α expression, and Met activation. (A) Hypoxia was detected by immunohistochemistry
staining of pimonidazole adducts in B16/F10 tumor sections from control and PLT-depleted mice. Nuclei were stained with hematoxylin. Hypoxia
was quantified as the percent hypoxic area per visual field. (B) Western blot analysis of HIF-1α expression in tumors from control and PLT-
depleted mice. Quantification of western blot analysis for HIF-1α (normalized to β-actin). (C) Western blot analysis of p-Met, total Met, and β-actin
expression in tumors from control and PLT-depleted mice. Quantification of western blot analysis for total Met (normalized to β-actin) and p-Met
(normalized to β-actin).
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cancer invasiveness on the expression and activation of
the proinvasive tyrosine kinase receptor Met [12,13], we
analyzed total protein and tyrosine phosphorylation
levels of Met in both platelet-depleted and control mice.
Western blotting analysis revealed that platelet depletion
caused a significant decrease of both total Met and
phospho-Met in tumors compared to tumors from con-
trol mice (Figure 4C).
Platelets changed intratumoral levels of angiogenic
factors
Proangiogenic growth factors released from platelet
granules can affect tumor cell survival, proliferation, or
invasiveness. Because our data indicated decreased hyp-
oxia in platelet-depleted tumors, we considered the pos-
sible involvement of growth factors known to regulate
tumor growth and metastasis. Previous studies demon-
strated that the angiogenic cascade of the Ang-Tie sys-
tem is critical for controlling vessel assembly and
maturation. We performed Western blotting to examine
the expression of Ang-1, which induces Tie2 activation
leading to vessel stabilization and maturation, and its an-
tagonist Ang-2, which causes vessel destabilization
[19,20]. We observed a significant reduction in Ang-1 inplatelet-depleted tumors compared to control tumors
(Figure 5A). In contrast, the Ang-2 level was signifi-
cantly increased in platelet-depleted tumors compared
to control tumors (Figure 5B). Since the VEGF protein is
bioactive as soluble protein in the extracellular space
[21], we next examined extracellular VEGF level of tu-
mors. Microdialysis was performed at 24 days before
sacrifice, and found a significant decrease of extracellular
VEGF in platelet-depleted tumors compared to control
tumors (p < 0.05) (Figure 5C). These data suggest that
platelets play a role in the secretion of growth factors in
the tumor microenvironment.
Platelets changed levels of TGF-β1, MMP-2,9, and PAI-1
Considering that platelet-derived TGF-β1 plays a key role
in regulating circulating cancer cell dissemination [3], we
measured the influence of platelets on systemic and local
TGF-β1 levels. Blood, extracellular microdialysate, and
tumor samples were obtained from platelet-depleted, con-
trol, and co-implantation of B16/F10 mice. A significant in-
crease in plasma TGF-β1 from co-implantation of B16/F10
group compared with B16/F10 alone (523 ± 49.75 pg/mL
Vs. 329 ± 36.27 pg/mL, p < 0.05). The plasma TGF-β1 level
of platelet-depleted mice was significantly lower than
in control mice (252 ± 25.83 pg/mL Vs. 329 ± 36.27 pg/mL,
Figure 5 Platelets changed intratumoral levels of angiogenic factors. (A), (B) Western blot analysis of Angiopoietin-1, 2 expression in tumors
from control and PLT-depleted mice. Quantification of western blot analysis for each protein (normalized to β-actin). (C) Microdialysis was used to
sample extracellular proteins in vivo. Extracellular VEGF level was measured by ELISA as described in Materials and Methods. The results are
expressed as the mean ± SEM. * p < 0.05. (n = 6 for each group).
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were found in microdialysates and tumor samples in which
the TGF-β1 level of PLT-depletion was significantly lower
than in control and co-implantation mice (Figure 6B
and C).
To better investigate the molecular mechanisms by
which platelet depletion reduces metastasis in the
tumor microenvironment, we further evaluated the
expression of proteins that are involved in regulating
the basal membrane and barrier cancer cell intrava-
sion. Zymographic analysis of microdialysates revealed
that the intensity of MMP-9 and MMP-2 bands in
PLT-depletion were lower than in control groups
(Figure 6D). Furthermore, MMP-9 and MMP-2 bands
in the co-implantation group were more intense
than in the control group. Plasminogen activator
inhibitor-1 (PAI-1) protein level was reduced in
platelet-depleted tumors compared with control and
co-implantation tumors (Figure 6E), suggesting a
lower capacity to cross through surrounding micro-
environment by degrading several components of the
extracellular matrix (ECM).Discussion
Many experimental studies using in vitro assays and
in vivo metastatic animal models have demonstrated a
mechanistic link between tumor cell dissemination and
platelet activation. Direct contact between platelets and
tumor cells has been observed in the primary tumor
microenvironment. Platelet involvement in primary
tumor growth and invasiveness has not well been recog-
nized. The process of metastasis initiation includes de-
tachment of tumor cells from the primary site and
migration to and intravasation into the blood vessel.
Several angiogenic molecules, including angiopoietins,
VEGF, and TGF-β, are abundant in platelets and may
affect the tumor microenvironment [1,2,22]. As a Tie2-
antagonist, Ang-2 mediates angiogenic sprouting and
vascular regression. We found that platelet-depleted tu-
mors exhibited an increase in Ang-2 levels, leading to a
delay in vessel maturation and diminished pericyte re-
cruitment to blood vessels that were highly permeable
and hemorrhagic. This finding is supported by the
recent observation that platelet depletion displayed a
significantly lower vessel density and poor vascular
Figure 6 Platelets changed levels of TGF-β1, MMP-2,9, and PAI-1. TGF-β1 levels were measured by ELISA in plasma (A), microdialysates
(B), and tumor hemogenates (C) as described in Materials and Methods. (D). Gel zymography analysis of MMP-2, 9 from microdialysates in tumors
from PLT-depleted, control mice. (E). Western blot analysis of PAI-1 expression in tumors from PLT-depleted, control mice (normalized to β-actin).
The results are expressed as the mean ± SEM. * p < 0.05.
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limb ischemia animal models [6].
Furthermore, it is well known that VEGF plays an im-
portant role in the initiation of tumor angiogenesis.
Platelet-derived TGF-β is known as an important growth
factor involved in circulating dissemination [3]. In fact,
TGF-β also provides proliferative signals to tumor cells,
which might contribute to the ECM breakdown that is
required for vessel invasion to occur [23]. We used mi-
crodialysis to examine the extracellular VEGF and TGF-
β levels in solid B16/F10 tumors, and the results showed
that platelet-depleted mice exhibited a decreased secre-
tion of both VEGF and TGF-β compared to control
mice. It should be noted that most serum VEGF is de-
rived from platelets, which are activated upon coagula-
tion [24]. Further studies are required to clarify the role
of platelets in the storage of VEGF released from the
tumors.
Tumor progression and metastasis are strongly related
to blood vessel maturation and stabilization in the
tumor microenvironment. Platelets are involved in ves-
sel maturation through multiple mechanisms, including
releasing platelet-derived factors and cytokines and regulat-
ing bone marrow-derived cell recruitment [5,25,26]. VE-
cadherin is crucial for vessel assembly and integrity during
angiogenesis [18,27,28]. Likely, increased intratumoral VE-cadherin expression might contribute to vessel lumen de-
velopment. VE-cadherin also promotes tumor progression
not only by contributing to tumor angiogenesis but also by
enhancing tumor cell proliferation via the TGF-β1 signaling
pathway in breast cancer [29]. Interestingly, we found a sig-
nificant decrease in VE-cadherin expression in platelet-
depleted tumors, suggesting that high VE-cadherin in
tumors may lead to an enlarged vessel lumen and is linked
to tumor progression in the presence of platelets.
Invasion through the ECM is an important step in
tumor metastasis. Cancer cells initiate invasion by ad-
hering to and spreading along blood vessel walls. Proteo-
lytic enzymes, such as MMP, degrade ECM surrounding
the blood vessels to allow cancer cells to invade. Alter-
natively, it is important to note that tumor metastasis is
associated with blood vessel maturation and stabilization
in the primary tumor. Intravasation of cancer cells does
not occur solely though the vessel wall but also through
the ECM (basement membrane). TGF-β1 is a crucial
factor in inducing tumor growth and metastasis through
up-regulating MMP-2, 9. Intratumoral TGF-β1 is consti-
tutively secreted by B16/F10 tumor cells, as well as by
direct platelet-tumor cell [30]. We found a significant
reduction of TGF-β1 in blood, extracellular space and
intracellular tumors from platelet-depleted tumor-bearing
mice. Circulating platelet-derived TGF-β1 has been
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the TGFβ/Smad and NF-kB pathways in cancer cells [3].
Our data demonstrated that platelet depletion reduced
metastasis and was further associated with decreased
ECM degradation and reduced expression of MMP-2, 9
and PAI-1. The ECM surrounding blood vessels plays a
critical role in the limitation of extravasation and intrava-
sation in the tumor microenvironment. Thus, it is possible
that platelet-promoted primary tumor metastasis is mainly
associated with the integrity of the ECM in the tumor
microenvironment as a part of vessel maturation.
Our data demonstrated that Platelet depletion strongly
reduced the expression and tyrosine phosphorylation of the
Met receptor in tumors. Met expression has been shown to
result from increased tumor hypoxia. Our data demon-
strated that platelet depletion decreased metastasis and was
associated with decreased HIF-1a. It is well documented
that tumor hypoxia is associated with vessel structure ab-
normalities, such as leakiness and destabilization by poor
coverage of pericytes, and with excessive proliferation of
tumor cells. A recent study demonstrated that platelet de-
pletion causes a decrease in tumor proliferation and delays
vessel maturation [7]. Either a change in excessive tumor
cell proliferation or impaired vessel maturation accelerates
tumor hypoxia. The impaired vessel maturation may lead
to an increase in the interstitial pressure due to leakage and
thus alter the blood flow because of the compression of
tumor vessel, thus likely reduce tumor perfusion. Although
we found that platelet depletion significantly reduced blood
vessel perfusion of tumors, in this study, the impaired tumor
angiogenesis and vessel maturation induced by platelet de-
pletion are not sufficient to cause significant tumor hypoxia.
It seems that tumor cell proliferation could play a major role
in causing hypoxia in the tumor microenvironment.
Platelet-tumor cell contact promotes the hematogenous
dissemination of tumor cells by activating the NF-κB path-
way [3]. Abundant platelets were detected in the tumor
microenvironment outside of the vasculature [7]. Indeed, a
previous study has shown that NF-κB is a key orchestrator
of innate immunity/inflammation in many cancers [31].
Labelle et al. identified the involvement of inflammatory cy-
tokines in the platelet-related NF-κB pathway [3]. HIF-1α is
an inflammatory response gene. Furthermore, the presence
of messengers of inflammation is strong associated with the
occurrence of vascular remodeling and angiogenesis.
Therefore reduced vessel density and/or function underlie,
cannot rule out completely the contribution of immune/in-
flammatory cells for platelet-induced phenotype.
Conclusions
In summary, our data provide direct evidence that plate-
let depletion reduce primary tumor metastasis and are
associated with tumor hypoxia, ECM changes and vessel
maturation in the tumor microenvironment.Additional file
Additional file 1: Platelet depletion showed no change in 4T1
tumor growth and reduced lung metastasis. (A) Orthotopic
implantation of 4T1 mouse mammary epithelial cancer cells into BALB/c
mice followed by injections every 3 days of GPI or control antibody after
the tumors reached ~500 mm3. (B) Representative images of H&E-stained
lung sections. Scale bar, 5 μm. Arrows point to metastatic areas.
High-magnification images of metastatic nodules are visualized.
Scale bar, 50 μm. (n = 6 for each group).
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